Anle138b

In Parkinson’s patients, alpha-synuclein proteins clump together to form fibrils, which presumably damage nerve cells. A research team has now shown how lipids bind to these fibrils and influence their arrangement. They also demonstrated how the drug candidate anle138b attaches to the lipidic fibrils. The findings could open up new diagnostic and therapeutic approaches. more

The chemical compound anle138b eases cognitive deficits and normalizes gene expression in a mouse model of Alzheimer’s disease and it seems to close harmful openings in the membrane of nerve cells as an international team of researchers including researchers of the MPI for Biophysical Chemistry found out. The scientists suggest that anle138b should be validated in clinical trials for its potential to treat Alzheimer’s and further neurodegenerative diseases. more

In cooperation with colleagues in Göttingen and Munich, researchers at the German Center for Neurodegenerative Diseases have analyzed a novel substance that could serve as a prototype for the development of drugs to treat Alzheimer’s and other brain diseases. This substance ameliorated disease symptoms in mice and improved their cognition. more